AXSM Axsome Therapeutics Inc

Price (delayed)

$91.75

Market cap

$4.4B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.56

Enterprise value

$4.28B

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people ...

Highlights
The revenue has soared by 60% YoY and by 16% from the previous quarter
AXSM's gross profit has surged by 58% year-on-year and by 16% since the previous quarter
The net income has plunged by 67% YoY and by 4.1% from the previous quarter
The equity has dropped by 63% year-on-year and by 29% since the previous quarter

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
48M
Market cap
$4.4B
Enterprise value
$4.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
42.37
Price to sales (P/S)
14.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.68
Earnings
Revenue
$291.49M
EBIT
-$305.72M
EBITDA
-$297.03M
Free cash flow
-$168.02M
Per share
EPS
-$6.56
Free cash flow per share
-$3.53
Book value per share
$2.17
Revenue per share
$6.13
TBVPS
$10.22
Balance sheet
Total assets
$548.23M
Total liabilities
$445.37M
Debt
$190.6M
Equity
$102.85M
Working capital
$276.46M
Liquidity
Debt to equity
1.85
Current ratio
2.48
Quick ratio
2.34
Net debt/EBITDA
0.42
Margins
EBITDA margin
-101.9%
Gross margin
90.3%
Net margin
-105.9%
Operating margin
-104.9%
Efficiency
Return on assets
-54.1%
Return on equity
-174.5%
Return on invested capital
-164.7%
Return on capital employed
-84.5%
Return on sales
-104.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
0.79%
1 week
-2.07%
1 month
8.04%
1 year
11.6%
YTD
15.28%
QTD
13.98%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$291.49M
Gross profit
$263.23M
Operating income
-$305.72M
Net income
-$308.55M
Gross margin
90.3%
Net margin
-105.9%
The company's operating income has shrunk by 76% YoY and by 4.4% QoQ
The net income has plunged by 67% YoY and by 4.1% from the previous quarter
The revenue has soared by 60% YoY and by 16% from the previous quarter
AXSM's gross profit has surged by 58% year-on-year and by 16% since the previous quarter

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
42.37
P/S
14.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.68
The EPS has plunged by 53% YoY and by 2% from the previous quarter
The P/B is 77% higher than the last 4 quarters average of 23.8 and 11% higher than the 5-year quarterly average of 37.9
The equity has dropped by 63% year-on-year and by 29% since the previous quarter
The revenue has soared by 60% YoY and by 16% from the previous quarter
The price to sales (P/S) is 5% higher than the last 4 quarters average of 14.1

Efficiency

How efficient is Axsome Therapeutics business performance
The ROE has plunged by 56% YoY and by 30% from the previous quarter
AXSM's ROA is down by 23% YoY and by 7% QoQ
The ROS has contracted by 10% YoY but it has grown by 10% from the previous quarter
The company's return on invested capital fell by 4.6% QoQ

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 23% more than its total liabilities
The quick ratio has contracted by 47% YoY and by 22% from the previous quarter
AXSM's current ratio is down by 45% year-on-year and by 23% since the previous quarter
Axsome Therapeutics's debt is 85% higher than its equity
The debt to equity has soared by 180% YoY and by 41% QoQ
The equity has dropped by 63% year-on-year and by 29% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.